PMID- 31619598
OWN - NLM
STAT- MEDLINE
DCOM- 20200604
LR  - 20200604
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Print)
IS  - 0918-2918 (Linking)
VI  - 59
IP  - 3
DP  - 2020 Feb 1
TI  - An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate 
      Cancer in Which Abiraterone Demonstrated Long-term Efficacy.
PG  - 395-399
LID - 10.2169/internalmedicine.3302-19 [doi]
AB  - We analyzed the ERG gene status using fluorescence in situ hybridization (FISH) 
      in two chemotherapy-naive cases with metastatic castration-resistant prostate 
      cancer (mCRPC) in which abiraterone demonstrated a long-term durable complete 
      response. FISH identified Class 1 Edel and Class 2+ Edel in case 1, and Class 1 
      Edel in case 2. Our experience suggests that abiraterone may be effective in 
      cases with mCRPC and ERG gene abnormalities, particularly Class 2+ Edel or Class 
      1 Edel. This is the first report of two cases with mCRPC that simultaneously 
      investigated the ERG gene status and clinical aspects, including image 
      evaluations and pathology.
FAU - Yoshizawa, Tsuyoshi
AU  - Yoshizawa T
AD  - Department of Urology, Nihon University School of Medicine, Japan.
FAU - Yamaguchi, Kenya
AU  - Yamaguchi K
AD  - Department of Urology, Nihon University School of Medicine, Japan.
FAU - Kawata, Nozomu
AU  - Kawata N
AD  - Department of Urology, Nihon University Hospital, Japan.
FAU - Ryuzaki, Hitomi
AU  - Ryuzaki H
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, Nihon 
      University Hospital, Japan.
FAU - Ogawa, Masahiro
AU  - Ogawa M
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, Nihon 
      University Hospital, Japan.
FAU - Obinata, Daisuke
AU  - Obinata D
AD  - Department of Urology, Nihon University School of Medicine, Japan.
FAU - Mochida, Junichi
AU  - Mochida J
AD  - Department of Urology, Nihon University School of Medicine, Japan.
FAU - Takahashi, Satoru
AU  - Takahashi S
AD  - Department of Urology, Nihon University School of Medicine, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20191017
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Androstenes)
RN  - 0 (ERG protein, human)
RN  - 0 (Transcriptional Regulator ERG)
RN  - 9PHQ9Y1OLM (Prednisolone)
SB  - IM
MH  - Aged
MH  - Androstenes/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis/*drug therapy
MH  - Prednisolone/*therapeutic use
MH  - Prostatic Neoplasms, Castration-Resistant/*drug therapy
MH  - Transcriptional Regulator ERG/*drug effects/genetics
MH  - Treatment Outcome
PMC - PMC7028414
OTO - NOTNLM
OT  - ERG gene
OT  - abiraterone
OT  - durable complete response
OT  - fluorescence in situ hybridization
OT  - metastatic castration-resistant prostate cancer
COIS- The authors state that they have no Conflict of Interest (COI).
EDAT- 2019/10/18 06:00
MHDA- 2020/06/05 06:00
PMCR- 2020/02/01
CRDT- 2019/10/18 06:00
PHST- 2019/10/18 06:00 [pubmed]
PHST- 2020/06/05 06:00 [medline]
PHST- 2019/10/18 06:00 [entrez]
PHST- 2020/02/01 00:00 [pmc-release]
AID - 10.2169/internalmedicine.3302-19 [doi]
PST - ppublish
SO  - Intern Med. 2020 Feb 1;59(3):395-399. doi: 10.2169/internalmedicine.3302-19. Epub 
      2019 Oct 17.